Navigation Links
Nektar Therapeutics to Present at the Deutsche Bank 34th Annual Health Care Conference in Boston
Date:5/12/2009

SAN CARLOS, Calif., May 12 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) is scheduled to present at the upcoming Deutsche Bank 34th Annual Health Care Conference in Boston at the Boston InterContinental Hotel on Monday, May 18, 2009 at 1:45 p.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until June 10, 2009.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own potentially high-value therapeutics that addresses unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. For more information on Nektar Therapeutics, please visit http://www.nektar.com.

    Nektar Contacts:

    Jennifer Ruddock
    Nektar Therapeutics
    650-631-4954
    jruddock@nektar.com

    Susan Noonan
    The SAN Group
    212-966-3650
    susan@sanoonan.com


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Nektar to Announce Third Quarter 2007 Financial Results on Wednesday, November 7, 2007, After the Close of U.S. Financial Markets
2. Nektar Therapeutics Announces Third Quarter 2007 Financial Results
3. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
4. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
6. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
7. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
8. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
9. Nektar Therapeutics Announces First Quarter 2008 Results
10. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
11. Nektar Therapeutics Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... NutraPre today announced the ... pregnant women to prevent morning sickness and promote overall heath. Engineered with advanced ... and taste of water. , “Imagine a pregnancy without morning sickness,” NutraPre CEO ...
(Date:5/23/2016)... Angeles, CA (PRWEB) , ... May 23, 2016 , ... ... surgeons have noted that, less than 1% of United Kingdom residents who could benefit ... UK’s National Health Service (NHS) increases the number of bariatric procedures it offers to ...
(Date:5/23/2016)... ... , ... NYDNRehab, a New York City-based physical therapy clinic , is ... this type of technology, which was developed by world-renowned researcher Dr. Christopher Powers of ... , With over 10 million sport injuries per year in the United ...
(Date:5/23/2016)... ... May 23, 2016 , ... The Society for Women’s Health ... to move on from that role. , “No one in Washington led the way ... said SWHR Founder Florence Haseltine, MD, PhD. “We offer our deep gratitude to Phyllis ...
(Date:5/23/2016)... , ... May 23, 2016 , ... ... care to residents of Westchester County for over 24 years, recently hosted its ... community members joined HOW for two remembrance ceremonies, each concluding with the release ...
Breaking Medicine News(10 mins):
(Date:5/20/2016)... 2016 - Revenue Forecasts ... Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine ... New Study Reveals Selling Opportunities and Revenue Prospects ... ,What is the future of biologics, especially new ... commercial analysis. Staying ahead in data and knowledge, ...
(Date:5/19/2016)... Calif. , May 19, 2016  According ... thirds of the world lacks basic diagnostic imaging. ... in the United States , ... to such technology. In fact, the WHO reports ... risk of avoidable or treatable death, simply due ...
(Date:5/19/2016)... According to a new market research report "Sunitinib Malate ... Germany , France , U.K., ... Japan )", published by MarketsandMarkets, The market is projected to ... from 2016 to 2021.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302 ... through 26 Pages and in-depth TOC on "Sunitinib Malate ...
Breaking Medicine Technology: